메뉴 건너뛰기




Volumn 36, Issue 36, 2015, Pages 2415-2424

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: Past, present, and the future

Author keywords

Cardiovascular disease; Hypercholesterol mia; Low density lipoprotein cholesterol; Proprotein convertase subtilisin kexin type 9 inhibitors

Indexed keywords

ALIROCUMAB; AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; BOCOCIZUMAB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

EID: 84942104125     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv174     Document Type: Review
Times cited : (105)

References (72)
  • 3
    • 79959694696 scopus 로고    scopus 로고
    • A meta-analysis of low-density lipoprotein cholesterol, non-highdensity lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
    • Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-highdensity lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-345
    • (2011) Circ Cardiovasc Qual Outcomes , vol.4 , pp. 337-345
    • Sniderman, A.D.1    Williams, K.2    Contois, J.H.3    Monroe, H.M.4    McQueen, M.J.5    De Graaf, J.6    Furberg, C.D.7
  • 4
    • 26244432388 scopus 로고    scopus 로고
    • Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, SourjinaT, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-1278
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3    Blackwell, L.4    Buck, G.5    Pollicino, C.6    Kirby, A.7    Sourjinat Peto, R.8    Collins, R.9    Simes, R.10
  • 5
    • 33746494465 scopus 로고    scopus 로고
    • Low density lipoprotein cholesterol, statins and cardiovascular events: A meta-analysis
    • Genser B, Marz W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 2006;95:393-404
    • (2006) Clin Res Cardiol , vol.95 , pp. 393-404
    • Genser, B.1    Marz, W.2
  • 7
    • 0038394566 scopus 로고    scopus 로고
    • Precursor convertases in the secretory pathway, cytosol and extracellular milieu
    • Seidah NG, Prat A. Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 2002;38:79-94
    • (2002) Essays Biochem , vol.38 , pp. 79-94
    • Seidah, N.G.1    Prat, A.2
  • 15
    • 17144363236 scopus 로고    scopus 로고
    • Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia
    • Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol 2005; 16:167-172
    • (2005) Curr Opin Lipidol , vol.16 , pp. 167-172
    • Maxwell, K.N.1    Breslow, J.L.2
  • 17
    • 13944265645 scopus 로고    scopus 로고
    • Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
    • Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161-165
    • (2005) Nat Genet , vol.37 , pp. 161-165
    • Cohen, J.1    Pertsemlidis, A.2    Kotowski, I.K.3    Graham, R.4    Garcia, C.K.5    Hobbs, H.H.6
  • 18
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264-1272
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hobbs, H.H.4
  • 19
    • 77953309816 scopus 로고    scopus 로고
    • PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses
    • Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010;55:2833-2842
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2833-2842
    • Benn, M.1    Nordestgaard, B.G.2    Grande, P.3    Schnohr, P.4    Tybjærg-Hansen, A.5
  • 20
    • 34447299120 scopus 로고    scopus 로고
    • The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    • Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193:445-448
    • (2007) Atherosclerosis , vol.193 , pp. 445-448
    • Hooper, A.J.1    Marais, A.D.2    Tanyanyiwa, D.M.3    Burnett, J.R.4
  • 21
    • 71849105837 scopus 로고    scopus 로고
    • Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: The Coronary Artery Risk Development in Young Adults Study
    • Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet 2009;2:354-361
    • (2009) Circ Cardiovasc Genet , vol.2 , pp. 354-361
    • Huang, C.C.1    Fornage, M.2    Lloyd-Jones, D.M.3    Wei, G.S.4    Boerwinkle, E.5    Liu, K.6
  • 22
    • 57649193160 scopus 로고    scopus 로고
    • Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
    • Atherosclerosis Risk in Communities (ARIC) Study Investigators
    • Folsom AR, Peacock JM, Boerwinkle E, Atherosclerosis Risk in Communities (ARIC) Study Investigators. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis 2009;202:211-215
    • (2009) Atherosclerosis , vol.202 , pp. 211-215
    • Folsom, A.R.1    Peacock, J.M.2    Boerwinkle, E.3
  • 33
    • 84872307169 scopus 로고    scopus 로고
    • PCSK9 Inhibitors: Potential in cardiovascular therapeutics
    • Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 2013;15:1-12
    • (2013) Curr Cardiol Rep , vol.15 , pp. 1-12
    • Do, R.Q.1    Vogel, R.A.2    Schwartz, G.G.3
  • 34
    • 34547108600 scopus 로고    scopus 로고
    • Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation
    • Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-18612
    • (2007) J Biol Chem , vol.282 , pp. 18602-18612
    • Zhang, D.W.1    Lagace, T.A.2    Garuti, R.3    Zhao, Z.4    McDonald, M.5    Horton, J.D.6    Cohen, J.C.7    Hobbs, H.H.8
  • 35
  • 38
    • 13844310887 scopus 로고    scopus 로고
    • Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
    • Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 2005;102:2069-2074
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 2069-2074
    • Maxwell, K.N.1    Fisher, E.A.2    Breslow, J.L.3
  • 41
    • 84921262461 scopus 로고    scopus 로고
    • On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
    • Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 2014;238: 264-270
    • (2014) Atherosclerosis , vol.238 , pp. 264-270
    • Tavori, H.1    Rashid, S.2    Fazio, S.3
  • 43
    • 84862219022 scopus 로고    scopus 로고
    • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
    • McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59: 2344-2353
    • (2012) J Am Coll Cardiol , vol.59 , pp. 2344-2353
    • McKenney, J.M.1    Koren, M.J.2    Kereiakes, D.J.3    Hanotin, C.4    Ferrand, A.C.5    Stein, E.A.6
  • 44
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolæmia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study
    • LAPLACE-TIMI 57 Investigators
    • Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolæmia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380: 2007-2017
    • (2012) Lancet , vol.380 , pp. 2007-2017
    • Giugliano, R.P.1    Desai, N.R.2    Kohli, P.3    Rogers, W.J.4    Somaratne, R.5    Huang, F.6    Liu, T.7    Mohanavelu, S.8    Hoffman, E.B.9    McDonald, S.T.10    Abrahamsen, T.E.11    Wasserman, S.M.12    Scott, R.13    Sabatine, M.S.14
  • 46
    • 84868689211 scopus 로고    scopus 로고
    • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    • Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367: 1891-1900
    • (2012) N Engl J Med , vol.367 , pp. 1891-1900
    • Roth, E.M.1    McKenney, J.M.2    Hanotin, C.3    Asset, G.4    Stein, E.A.5
  • 48
    • 84900303213 scopus 로고    scopus 로고
    • Effect of evolocumab or ezetimibe added to moderate- or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
    • LAPLACE-2 Investigators
    • Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-1882
    • (2014) JAMA , vol.311 , pp. 1870-1882
    • Robinson, J.G.1    Nedergaard, B.S.2    Rogers, W.J.3    Fialkow, J.4    Neutel, J.M.5    Ramstad, D.6    Somaratne, R.7    Legg, J.C.8    Nelson, P.9    Scott, R.10    Wasserman, S.M.11    Weiss, R.12
  • 49
  • 50
    • 84892679366 scopus 로고    scopus 로고
    • Efficacy and safety of longer-termadministration of evolocumab(AMG145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial
    • Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R,Wasserman SM, Sabatine MS. OSLER Investigators. Efficacy and safety of longer-termadministration of evolocumab(AMG145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014;129: 234-243
    • (2014) Circulation , vol.129 , pp. 234-243
    • Koren, M.J.1    Giugliano, R.P.2    Raal, F.J.3    Sullivan, D.4    Bolognese, M.5    Langslet, G.6    Civeira, F.7    Somaratne, R.8    Nelson, P.9    Liu, T.10    Scott, R.11    Wasserman, S.M.12    Sabatine, M.S.13
  • 51
    • 84929322473 scopus 로고    scopus 로고
    • Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolæmia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial
    • Colhoun HM. for the ODYSSEY COMBO II Investigators, Feb 16
    • Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. for the ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolæmia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015; Feb 16
    • (2015) Eur Heart J
    • Cannon, C.P.1    Cariou, B.2    Blom, D.3    McKenney, J.M.4    Lorenzato, C.5    Pordy, R.6    Chaudhari, U.7
  • 57
    • 84874956296 scopus 로고    scopus 로고
    • Management of familial hypercholesterolemia: A review of the recommendations from the National Lipid Association Expert Panelon Familial Hypercholesterolemia
    • Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panelon Familial Hypercholesterolemia. J Manag Care Pharm 2013;19:139-149
    • (2013) J Manag Care Pharm , vol.19 , pp. 139-149
    • Robinson, J.G.1
  • 58
    • 2542461241 scopus 로고    scopus 로고
    • Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal
    • O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J AmColl Cardiol 2004;43:2142-2146
    • (2004) J AmColl Cardiol , vol.43 , pp. 2142-2146
    • O'Keefe, J.H.1    Cordain, L.2    Harris, W.H.3    Moe, R.M.4    Vogel, R.5
  • 59
    • 84922938167 scopus 로고    scopus 로고
    • CannonCP.IMPROVE-IT trial: Acomparisonof ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes
    • CannonCP.IMPROVE-IT trial: acomparisonof ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation 2014;130:2105-2126
    • (2014) Circulation , vol.130 , pp. 2105-2126
  • 60
    • 52049116959 scopus 로고    scopus 로고
    • Clinical characterization and molecular mechanisms of statin myopathy
    • Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008;6:955-969
    • (2008) Expert Rev Cardiovasc Ther , vol.6 , pp. 955-969
    • Toth, P.P.1    Harper, C.R.2    Jacobson, T.A.3
  • 64
    • 22044444971 scopus 로고    scopus 로고
    • Total first-year costs of acute coronary syndrome in a managed care setting
    • Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-306
    • (2005) J Manag Care Pharm , vol.11 , pp. 300-306
    • Etemad, L.R.1    McCollam, P.L.2
  • 67
    • 74549114679 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolæmia
    • Nherera L, Calvert NW, Demott K, Humphries SE, Neil HA, Minhas R, Thorogood M. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolæmia. Curr Med Res Opin 2010;26:529-536
    • (2010) Curr Med Res Opin , vol.26 , pp. 529-536
    • Nherera, L.1    Calvert, N.W.2    Demott, K.3    Humphries, S.E.4    Neil, H.A.5    Minhas, R.6    Thorogood, M.7
  • 69
    • 84885447918 scopus 로고    scopus 로고
    • Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis
    • Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013;62:1401-1408
    • (2013) J Am Coll Cardiol , vol.62 , pp. 1401-1408
    • Urban, D.1    Pöss, J.2    Böhm, M.3    Laufs, U.4
  • 70
    • 84925351969 scopus 로고    scopus 로고
    • Lipid lowering with PCSK9 inhibitors
    • Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014; 11:563-575
    • (2014) Nat Rev Cardiol , vol.11 , pp. 563-575
    • Dadu, R.T.1    Ballantyne, C.M.2
  • 71
    • 84939568663 scopus 로고    scopus 로고
    • Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
    • Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, Wu R, Dufour R. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med 2015;127:125-132
    • (2015) Postgrad Med , vol.127 , pp. 125-132
    • Koren, M.J.1    Roth, E.M.2    McKenney, J.M.3    Gipe, D.4    Hanotin, C.5    Ferrand, A.C.6    Wu, R.7    Dufour, R.8
  • 72
    • 84914703551 scopus 로고    scopus 로고
    • PCSK9 antibodies for the treatment of hypercholesterolemia
    • Gouni-Berthold I, Berthold HK. PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients 2014;6:5517-5533
    • (2014) Nutrients , vol.6 , pp. 5517-5533
    • Gouni-Berthold, I.1    Berthold, H.K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.